U.S. Food and Drug Administration (FDA) Approves Foundationone Liquid Cdx as a Companion Diagnostic for Akeega (Niraparib and Abiraterone Acetate) for Patients With Brca-Positive Metastatic Castration-Resistant Prostate Cancer
美國食品和藥品監督管理局（FDA）批准Foundationone Liquid Cdx作爲Akeega（Niraparib和Abiraterone Acetate）的伴隨診斷工具，用於BRCA陽性轉移性去勢抵抗前列腺癌患者。